Immunis, Inc., a clinical-stage biotech pioneering multi-active stem cell-derived biologics for age and disease-related immune dysregulation, today announced it has been named one of the Top 50 Healthcare Technology Companies of 2025 by The Healthcare Technology Report, recognizing notable advances in next-generation therapeutics, care delivery and clinical insights. The recognition follows the company’s recent publication in Obesity showing body fat loss and increased lean muscle mass, a first-in-class phase 2 trial of its treatment candidate for sarcopenic obesity, and Series A financing.

“Age-related diseases are driven by numerous biological factors and need to be treated with multi-active therapeutics that can address the cellular complexities of disease and engage the immune system,” said Immunis’ Chief Science Officer, Dr. Tom Lane. “This significant validation of Immunis’ progress toward changing the course of immune-related diseases and aging with a novel biologic supports our commitment to pioneering new frontiers in regenerative medicine.”

The company’s unique approach focuses on harnessing the power of the secretome (the collection of signaling proteins secreted by cells) to naturally influence tissue regeneration and improve function in aging patients.

The selection committee considers thousands of organizations based on product quality, management team strength, technological innovation, and overall industry impact. Earlier this year, Immunis was also named a Top 25 Biotech and Life Sciences Company by the organization.

Immunis will be formally honored in New York City at an event taking place on March 5, 2026.

About Immunis Inc.

Immunis is a clinical-stage biotechnology company developing multi-active stem cell-derived biologics for the various manifestations of age-related diseases and immune dysregulation. The investigational product line leverages Immunis’ leading-edge capabilities in stem cell secretome technology to deliver a product of all natural, all human immune modulators in their natural physiological concentrations. For additional information about Immunis’ programs, please visit Immunisbiomedical.com.

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.

Press Contact

Shira Derasmo, Cuttlefish Communications

917-280-2497 | shira@cuttlefishpr.com

Investor Relations Contact

Mark Cabato, Chief Business Officer, Immunis, Inc.

mark@immunisbiomedical.com